Show Summary Details
Page of

Brain injury biomarkers in the critically ill 

Brain injury biomarkers in the critically ill
Brain injury biomarkers in the critically ill

Patrick M. Kochanek

and Rachel P. Berger

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 May 2022

A variety of biomarkers of brain injury are being developed in neurocritical care to study secondary injury pathways or aid in diagnostic, prognostic, and/or theragnostic applications. This chapter focuses largely on brain injury biomarkers that can be detected in serum or cerebrospinal fluid samples from patients with acute critical brain injury of various causes. Much of the work has been carried using biomarkers of proteins that are relatively unique to the brain, and that reflect damage to important cellular constituents such as neurons, astroycytes, or axons. Novel approaches that employ a panel of markers or novel analytic methods such as trajectory analysis may optimize the utility of these biomarkers in clinical practice. We anticipate that there will soon be one or more protein biomarkers of brain injury available for clinical use.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.